Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.

2.50
Hdl Handle:
http://hdl.handle.net/10541/75853
Title:
Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Authors:
Cortesi, Enrico; Gascon, Pere; Henry, David; Littlewood, Timothy; Milroy, Robert; Pronzato, Paolo; Reinhardt, Uwe; Shasha, Daniel; Thatcher, Nick; Wilkinson, Peter M
Abstract:
The introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level <12 g/dl) cancer patients undergoing chemotherapy. Increased Hb improves patients' energy level and their ability to perform the activities of daily living, as well as their overall quality of life (QOL). These findings are independent of tumor type and disease status and are comparable in patients receiving nonplatinum- and platinum-based chemotherapeutic regimens. Furthermore, more than a decade of use in clinical trials and by physicians in routine clinical practice has demonstrated that epoetin alfa is safe and well tolerated when used to treat cancer patients with anemia. The availability of epoetin alfa as an alternative to transfusion has changed practices in anemia management; physicians can now treat anemia with the goal of achieving adequate Hb levels to relieve anemia-related fatigue, a major symptom contributing to decreased QOL in cancer patients. Incremental benefit analysis has shown that increasing Hb level from 11 g/dl to 12 g/dl yields the greatest improvement in QOL per 1 g/dl increase in Hb. The demonstrated efficacy of epoetin alfa for increasing Hb levels and improving patient QOL have made this agent a rationale choice for management of cancer-related anemia. Ongoing research will continue to provide new insights into best management of anemia with epoetin alfa in cancer patients.
Affiliation:
Dipartimento Medicina Sperimentale e Patologia, Università di Roma, Rome, Italy.
Citation:
Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life. 2005, 68 Suppl 1:22-32 Oncology
Journal:
Oncology
Issue Date:
2005
URI:
http://hdl.handle.net/10541/75853
DOI:
10.1159/000083130
PubMed ID:
15855813
Type:
Article
Language:
en
ISSN:
0030-2414
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCortesi, Enrico-
dc.contributor.authorGascon, Pere-
dc.contributor.authorHenry, David-
dc.contributor.authorLittlewood, Timothy-
dc.contributor.authorMilroy, Robert-
dc.contributor.authorPronzato, Paolo-
dc.contributor.authorReinhardt, Uwe-
dc.contributor.authorShasha, Daniel-
dc.contributor.authorThatcher, Nick-
dc.contributor.authorWilkinson, Peter M-
dc.date.accessioned2009-07-29T12:39:38Z-
dc.date.available2009-07-29T12:39:38Z-
dc.date.issued2005-
dc.identifier.citationStandard of care for cancer-related anemia: improving hemoglobin levels and quality of life. 2005, 68 Suppl 1:22-32 Oncologyen
dc.identifier.issn0030-2414-
dc.identifier.pmid15855813-
dc.identifier.doi10.1159/000083130-
dc.identifier.urihttp://hdl.handle.net/10541/75853-
dc.description.abstractThe introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level <12 g/dl) cancer patients undergoing chemotherapy. Increased Hb improves patients' energy level and their ability to perform the activities of daily living, as well as their overall quality of life (QOL). These findings are independent of tumor type and disease status and are comparable in patients receiving nonplatinum- and platinum-based chemotherapeutic regimens. Furthermore, more than a decade of use in clinical trials and by physicians in routine clinical practice has demonstrated that epoetin alfa is safe and well tolerated when used to treat cancer patients with anemia. The availability of epoetin alfa as an alternative to transfusion has changed practices in anemia management; physicians can now treat anemia with the goal of achieving adequate Hb levels to relieve anemia-related fatigue, a major symptom contributing to decreased QOL in cancer patients. Incremental benefit analysis has shown that increasing Hb level from 11 g/dl to 12 g/dl yields the greatest improvement in QOL per 1 g/dl increase in Hb. The demonstrated efficacy of epoetin alfa for increasing Hb levels and improving patient QOL have made this agent a rationale choice for management of cancer-related anemia. Ongoing research will continue to provide new insights into best management of anemia with epoetin alfa in cancer patients.en
dc.language.isoenen
dc.subjectAnaemiaen
dc.subjectHaematinicsen
dc.subjectHaemoglobinsen
dc.subjectCanceren
dc.subject.meshAnemia, Hypochromic-
dc.subject.meshControlled Clinical Trials as Topic-
dc.subject.meshEpoetin Alfa-
dc.subject.meshErythropoietin, Recombinant-
dc.subject.meshHematinics-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshQuality of Life-
dc.subject.meshSeverity of Illness Index-
dc.titleStandard of care for cancer-related anemia: improving hemoglobin levels and quality of life.en
dc.typeArticleen
dc.contributor.departmentDipartimento Medicina Sperimentale e Patologia, Università di Roma, Rome, Italy.en
dc.identifier.journalOncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.